NantKwest, Inc. (NASDAQ:NK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm presently has a $5.75 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential upside of 12.30% from the stock’s current price.

According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “

Other equities research analysts also recently issued research reports about the company. ValuEngine upgraded NantKwest from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 14th. BidaskClub cut NantKwest from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, Citigroup Inc. set a $3.00 price objective on NantKwest and gave the stock a “sell” rating in a research note on Monday, August 14th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $5.44.

NantKwest (NASDAQ:NK) opened at 5.12 on Wednesday. The firm’s market cap is $406.73 million. The company has a 50 day moving average price of $5.56 and a 200-day moving average price of $5.56. NantKwest has a 52-week low of $4.35 and a 52-week high of $7.95.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/11/nantkwest-inc-nk-upgraded-by-zacks-investment-research-to-buy.html.

In related news, Director Steve Gorlin sold 39,604 shares of NantKwest stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $5.93, for a total transaction of $234,851.72. Following the completion of the sale, the director now directly owns 246,280 shares of the company’s stock, valued at $1,460,440.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 70.19% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of NK. Renaissance Technologies LLC grew its stake in NantKwest by 1,884.1% in the first quarter. Renaissance Technologies LLC now owns 486,100 shares of the biotechnology company’s stock valued at $1,726,000 after acquiring an additional 461,600 shares during the period. Vanguard Group Inc. grew its stake in NantKwest by 8.4% in the first quarter. Vanguard Group Inc. now owns 2,082,706 shares of the biotechnology company’s stock valued at $7,394,000 after acquiring an additional 160,510 shares during the period. Northern Trust Corp grew its stake in NantKwest by 67.8% in the second quarter. Northern Trust Corp now owns 304,062 shares of the biotechnology company’s stock valued at $2,308,000 after acquiring an additional 122,906 shares during the period. State Street Corp grew its stake in NantKwest by 52.9% in the second quarter. State Street Corp now owns 341,007 shares of the biotechnology company’s stock valued at $2,589,000 after acquiring an additional 117,946 shares during the period. Finally, Alps Advisors Inc. acquired a new position in NantKwest in the second quarter valued at about $563,000. 18.79% of the stock is owned by hedge funds and other institutional investors.

NantKwest Company Profile

Get a free copy of the Zacks research report on NantKwest (NK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.